Resolution No. 6/08-2                             
 
ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES 
 
VACCINES FOR CHILDREN PROGRAM 
 
VACCINES TO PREVENT HUMAN PAPILLOMAVIRUS (HPV) INFECTION 
 
The purpose of this resolution is to update the dose intervals for the quadrivalent HPV.

VFC resolution 6/06-2 is repealed and replaced by the following:  
 
Eligible groups 
Females 9 through 18 years of age. 
 
Recommended schedule for quadrivalent HPV vaccine 
A 3-dose series for the quadrivalent HPV vaccine is recommended for females at age 11 to 12 years old with the following schedule: 
 
1st dose: at elected date 
2nd dose: 2months after the first dose 
3rd dose: 6 months after the first dose 
        
Minimum age and intervals for quadrivalent HPV vaccine  
Minimum Age             
9 years old                        
 
Dose 1 to 2
4 weeks

Dose 2 to 3					
12 weeks (and 24 weeks after the first dose)


Catch-up vaccination 
Vaccination is recommended for females 13 through 18 years of age who have not been previously vaccinated 
or who have not completed the full series.   
 
Other vaccination  
Eligible females as young as 9 years of age can be vaccinated.  
 
Interrupted vaccine schedules  
If the quadrivalent HPV vaccine schedule is interrupted, the vaccine series does not need to be restarted. 
If the series is interrupted after the first dose, the second dose should be given as soon as possible, and the second 
and third doses should be separated by an interval of at least 12 weeks.  If only the third dose is delayed, it should be administered as soon as possible.  
  
 
Recommended dosage  
Refer to product package inserts. 
 
Special situations 
Immunocompromised persons 
Because quadrivalent HPV vaccine is a subunit vaccine, it can be administered to persons who are immunosuppressed as a result
 of disease or medications; however, the immune response to the vaccine might be less than that in persons who are immunocompetent.     
 
Vaccination during pregnancy 
Quadrivalent HPV vaccine is not recommended for use in pregnancy. The vaccine has not been causally associated with adverse 
outcomes of pregnancy or adverse events to the developing fetus.  However, data on vaccination in pregnancy are limited.  
Until further information is available, initiation of the vaccine series should be delayed until after completion of the pregnancy.  
If a woman is found to be pregnant after initiating the vaccination series, completion of the 3-dose regimen should be delayed until 
after completion of the pregnancy.  If a vaccine dose has been administered during pregnancy, there is no indication for any intervention.  
A vaccine in pregnancy registry has been established; patients and health-care providers are encouraged to report any exposure to 
quadrivalent HPV vaccine during pregnancy by calling (800) 986-8999. 
 
Lactating women 
Lactating Women can receive HPV vaccine. 
 
Precautions and contraindications 
 
Acute illnesses 
Quadrivalent HPV vaccine can be administered to persons with minor acute illnesses (e.g., diarrhea or mild upper respiratory track infections, with or without fever).   
Vaccination of persons with moderate or severe acute illnesses should be deferred until after the illness improves.  
 
Immediate hypersensitivity or allergy to vaccine components 
Quadrivalent HPV vaccine is contraindicated for persons with a history of immedicate hypersensitivity to yeast or to any vaccine component. 
Despite a theoretic risk for allergic reaction to vaccination in persons with allergy to Saccharomyces cerevisiae (baker’s yeast), no adverse reactions 
have been documented after vaccination of persons with a history of yeast allergy.  
 
Adopted and Effective: June 25, 2008
      


This document can be found on the CDC website at:
http://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/0608hpv.txt